Ovary Cancer Clinical Trial
Official title:
CT Detected Tumour Infiltration Patterns of the Mesentery in High Grade Ovarian Carcinoma (HGSOC) Patients, Their Role in Treatment Planning and Outcome Prediction and How Machine Learning Can be Applied to Identify Them.
To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Recruiting |
NCT05081765 -
The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib
|
||
| Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Recruiting |
NCT05887609 -
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
|
Phase 2 | |
| Recruiting |
NCT05990426 -
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
|
N/A | |
| Recruiting |
NCT05059782 -
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
|
N/A | |
| Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
| Recruiting |
NCT05187338 -
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05080556 -
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT06161233 -
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy
|
N/A | |
| Recruiting |
NCT06256055 -
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04000880 -
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
|
N/A | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 |